Removal and Inactivation of Hepatitis A Virus during Manufacture of a High Purity Antihemophilic Factor VIII Concentrate from Human Plasma

Journal of Microbiology

Volumn 39, Issue 1, 2001, Pages 67-73

  Kim, In Seop ^a   Choi, Yong Woon ^a   Lee, Sung Rae ^a   Lee, Mahl Soon ^a   Huh, Ki Ho ^a   Lee, Soungmin ^a  

^a Green Cross Company   (South Korea)

Author keywords

Antihemophilic factor VIII; Hepatitis A virus; Inactivation; Log reduction factor; Removal

Indexed keywords

EID: 0347670027     PISSN: 12258873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Addiego, Jr., J. E., E. Gomperts, S. Liu, P. Bailey, S. G. Courter, M. L. Lee, G. G. Neslund, H. S. Kingdon, and M. J. Griffith. 1992. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by Anti-FVIIIc immunoaffinity chromatography. Thromb. Haemost. 67, 19-27.
2. Andrewes, C. 1989. Andrewes Viruses of Vertebrates, p. 120-145. Balliere Tindal, London.
3. Gomperts, E. 1988. Hemofil® M: Characteristics, pharmacokinetics, efficacy and safety, p. 41-47. In H. R. Roberts (ed.), Biotechnology and the promise of pure factor VIII. Baxter Scientific Publications, Brussels.
4. Grinde, B., K. Stene-Johansen, B. Sharma, T. Hoel, M. Jensenius, and K. Skaug. 1997. Characterization of an epidemic of hepatitis A virus involving intravenous drug abusers-infection by needle sharing. J. Med. Virol. 53, 69-75.
5. Hamman, J., J. Zou, and B. Horowitz. 1994. Removal and inactivation of hepatitis A virus (HAV) during processing of factor VIII concentrates. Vox Sang. 67(Suppl. 1), 72-77.
6. Hart, H. F., W. G. Hart, J. Crossley, A. M. Perrie, D. J. Wood, A. John, and F. McOmish . 1994. Effect of terminal (dry) heat treatment on non-enveloped viruses in coagulation factor concentrates. Vox Sang. 67, 345-350.
7. Horowitz, B., A. Lazo, H. Grossberg, G. Page, A. Lippin, and G. Swan. 1998. Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma. Vox Sang. 74 (Suppl. 1), 203-206.
8. Horowitz, M. S., C. Rooks, B. Horowitz, and M. W. Hilgartner. 1986. Virus safety of solvent/detergent treated antihaemophiliac factor concentrates. Lancet 2, 186-189.
9. Horowitz, B. 1990. Blood protein derivative viral safety: Observations and Analysis. Yale J. Med. 63, 361-369.
10. Hoyer, L. W. 1994. Hemophilia A. N. Engl. J. Med. 330, 38.
11. International Conference on Harmonisation. 1998. Guidance on Viral safety Evaluation of Biotechnology Products Derived From Cell Lines of Human or Animal Origin; Availability. Federal Resister 63(185), 51074-51084.
12. Johnson, Z., L. Thornton, A. Tobin, E. Lawlor, J. Power, I. Hillary, and I. Temperley. 1995. An outbreak of hepatitis A among Irish haemophiliacs. Int. J. Epidermol. 24, 821-828.
13. Kim, I. S., Y. W. Choi, H. S. Woo, C. E. Chang, and S. Lee. 2000. Solvent/detergent inactivation and Chromatographic removal of human immunodeficiency virus during the manufacturing of a high purity antihemophilic factor VIII concentrate. J. Microbiol. 38, 187-191.
14. Lemon, S. M., P. C. Murphy, A. Smith, J. Zou, J. Hammon, S. Robinson, and B. Horowitz. 1994. Removal/neutralization of hepatitis A virus during manufacture of high purity, solvent/ detergent factor VIII concentrate. J. Med. Virol. 43, 44-49.
15. Mannucci, P. M. 1992. Outbreak of hepatitis A among Italian patients with hemophilia. Lancet 339, 819.
16. Mannucci, P. M. 1993. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates. Vox Sang. 64, 197-203.
17. Mosley, J. W. and J. Rakela. 1999. Foundling viruses and transfusion medicine. Transfusion 39, 1041-1044.
18. Nowak, T., M. Niedrig, D. Bernhardt, and J. Hilfenhause. 1993. Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivatives by pasteurization. Dev. Biol. Stand. 81, 169-176.
19. Peerlinck, K. and J. Vermylen. 1993. Acute hepatitis A in patients with haemophilia A. Lancet 341, 179.
20. Prince, A. M., B. Horowitz, and B. Brotman. 1986. Sterilization of hepatitis and HTLV III viruses by exposure to Tri-n-Butyl phosphate and sodium cholate. Lancet 1, 706-710.
21. Robinson, S. M., H. Schwinn, and A. Smith. 1992. Clotting factors and hepatitis A. Lancet 340, 1465.
22. Temperley, I. J., K. P. Cotter, T. J. Walsh, J. Power, and I. B. Hillary. 1992. Clotting factors and hepatitis A. Lancet 340, 1466.
23. The European Agency for the Evaluation of Medicinal Products: Human Medicines Evaluation Unit. Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on Virus validation Studies: The Design, Contribution and Interpretation of Studies Validating the Inactivation and Removal of Viruses (CPMP/BWP/268/95).
24. The European Agency for the Evaluation of Medicinal Products: Human Medicines Evaluation Unit. Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on Plasma Derived Medicinal Products (CPMP/BWP/269/95 rev2).
25. The European Agency for the Evaluation of Medicinal Products: Human Medicines Evaluation Unit. Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on Quality of Biotechnology Products: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin (CPMP/ICH/295/95).